Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The Netherlands Cancer Institute
With
Bristol-Myers Squibb
Early response evaluation with 18F-FDG PET/CT and immunological profiling of circulating immune cells and tumor-draining lymph nodes in non-small cell lung cancer patients treated with immunotherapy.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
willing and able to provide written informed consent for the study.
≥ 18 years of age on day of signing informed consent.
confirmed diagnosis of NSCLC.
Histological tumor biopsy for PD-L1 IHC assessment (DAKO assay) available.
Ipsilateral hilar or mediastinal lymph node with a short axis diameter ≥1 cm.
Eligible and planned to receive nivolumab according to EMA label and national guidelines.
Measurable disease according to RECIST v1.1.
WHO performance status of 0-2.
You may not be if
Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to baseline PET-scan.
Has an active infection or had an active infection within 2 weeks prior to baseline PET-scan.
Has a known history of hypersensitivity to contrast material.
Isolated distant relapse after curative intent treatment for stage I-III NSCLC.